CAPG Regulates Doxorubicin Resistance in Hepatocellular Carcinoma Cells via TGFB1 /Smad/Nrf2 Signalling Pathway
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70847 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Yue Shang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China. Hauptthemen laut MEDLINE: Doxorubicin, Carcinoma, Hepatocellular, Drug Resistance, Neoplasm, Liver Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jilin Provincial Natural Science Foundation (General Project of Free Exploration), Liaoning Provincial Natural Science Foundation, Doctoral Research Initiation Project, The National Natural Science Foundation of China.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a common and deadly type of liver cancer with limited treatment options and a considerable issue with chemoresistance. This study investigates the role of the cytoskeleton‐associated protein G (CAPG) gene in HCC and explores its expression, clinical relevance, as well as the molecular mechanisms on doxorubicin (Dox) resistance. Employing bioinformatics, immunohistochemistry, cell‐based assays and animal models, we systematically explored CAPG's function in HCC. Our results demonstrated that CAPG was markedly upregulated in HCC tissues and cell lines compared to normal controls (*** p < 0.001). High CAPG expression was associated with poor overall survival (HR = 1.98, p < 0.001) and unfavourable clinicopathological parameters, indicating its potential as a prognostic biomarker. Functional experiments indicated that CAPG knockdown significantly reduced viability and proliferation in Dox‐resistant HCC cells (*** p < 0.01). Conversely, overexpression promoted resistance. Mechanistically, CAPG appears to modulate ferroptosis via the TGFB1/Smad2/NRF2 signalling pathway, as supported by GSEA analysis and subsequent molecular assays. In vivo, CAPG knockdown in combination with Dox treatment significantly inhibited tumour growth in nude mouse models (*** p < 0.01). These findings suggest that CAPG is a pivotal regulator of HCC progression and chemoresistance, offering a promising prognostic biomarker and combinatorial therapeutic target to overcome Dox resistance in clinical settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
- Department of Histology and Embryology, School of Basic Medical Sciences, Jilin Medical University, Jilin, Jilin, China.
ORCID-Profile: Tingting Liu
Förderung
- Jilin Provincial Natural Science Foundation (General Project of Free Exploration)
- Liaoning Provincial Natural Science Foundation, Doctoral Research Initiation Project
- The National Natural Science Foundation of China
- Natural Science Foundation of Jilin Province
- Natural Science Foundation of Liaoning Province
Zitieren
APA
Shang, Y., Zhang, J., & Liu, T. (2025). CAPG Regulates Doxorubicin Resistance in Hepatocellular Carcinoma Cells via TGFB1 /Smad/Nrf2 Signalling Pathway. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70847
Vancouver
Shang Y, Zhang J, Liu T. CAPG Regulates Doxorubicin Resistance in Hepatocellular Carcinoma Cells via TGFB1 /Smad/Nrf2 Signalling Pathway. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70847
BibTeX
@article{Shang2025,
author = {Shang, Yue and Zhang, Jun and Liu, Tingting},
title = {CAPG Regulates Doxorubicin Resistance in Hepatocellular Carcinoma Cells via TGFB1 /Smad/Nrf2 Signalling Pathway},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70847}
}
EUVIMED